Methodological considerations for the quantification of self-reported caffeine use

Objective measures of smoking and caffeine intake and the risk of adverse pregnancy outcomes

BACKGROUND

In pregnancy, women are encouraged to cease smoking and limit caffeine intake. We employed objective definitions of smoking and caffeine exposure to assess their association with adverse outcomes.

METHODS

We conducted a case cohort study within the Pregnancy Outcome Prediction study to analyse maternal serum metabolomics in samples from 12, 20, 28 and 36 weeks of gestational age. Objective smoking status was defined based on detectable cotinine levels at each time point and objective caffeine exposure was based on tertiles of paraxanthine levels at each time point. We used logistic and linear regression to examine the association between cotinine, paraxanthine and the risk of pre-eclampsia, spontaneous pre-term birth (sPTB), fetal growth restriction (FGR), gestational diabetes mellitus and birthweight.

RESULTS

There were 914 and 915 women in the smoking and caffeine analyses, respectively. Compared with no exposure to smoking, consistent exposure to smoking was associated with an increased risk of sPTB [adjusted odds ratio (aOR) = 2.58, 95% CI: 1.14 to 5.85)] and FGR (aOR = 4.07, 95% CI: 2.14 to 7.74) and lower birthweight (β = -387 g, 95% CI: -622 g to -153 g). On univariate analysis, consistently high levels of paraxanthine were associated with an increased risk of FGR but that association attenuated when adjusting for maternal characteristics and objective-but not self-reported-smoking status.

CONCLUSIONS

Based on objective data, consistent exposure to smoking throughout pregnancy was strongly associated with sPTB and FGR. High levels of paraxanthine were not independently associated with any of the studied outcomes and were confounded by smoking.

Caffeinated non-alcoholic beverages on the postpartum mental health related to the COVID-19 pandemic by a cross-sectional study in Argentina

Purpose

This work aimed to study postpartum mental outcomes and determinants of the intake of caffeinated beverages during the pandemic in women from Argentina.

Methods

This cross-sectional study recruited 619 women who responded to online self-report questionnaires during the first and second waves of COVID-19, including validated instruments (Insomnia Severity Index, Perceived Stress Scale, Postpartum Depression Screening Scale, Memory Complaint Scale, and Breastfeeding Self-Efficacy Scale), and general data. Intake frequency and amount of caffeinated beverages were estimated. Multivariate regression and structural equation models identified associations and effects (p < 0.05).

Results

Women were under social restrictions for 60.39 days, with home and essential activities increasing caffeinated intake. They ingested (mL/d): yerba mate (1457.71), coffee (66.85), tea (67.61), and soft drinks (50.95), which provided 646.20 mg/d of caffeine. Intakes of coffee and yerba mate were higher than pre-pandemic ones. Coffee was positively associated with stress and insomnia, and indirectly linked to higher levels of depression and memory complaints, and lower breastfeeding self-efficacy. Tea showed a similar but weaker association. Yerba mate correlated inversely with depression (through direct pathways), insomnia, and memory complaints (through indirect pathways), promoting breastfeeding self-efficacy. Soft drinks and caffeine did not present significant associations.

Conclusion

Although findings do not imply causation, results suggest that beverages would exhibit caffeine-independent affective and cognitive roles, which might be anxiogenic in the case of coffee and tea (to a lesser extent). Yerba mate showed antidepressant potential. Given that breastfeeding might be compromised during the pandemic, yerba mate intake is promissory to protect postpartum mental health.

The impact of genetic variability on the relationship between caffeine and cardiometabolic outcomes: A systematic review

The relationship between caffeine consumption and cardiometabolic health has been reported, however with heterogenous results. Discrepancies in study results may be due to inter-individual variability between study participants. This systematic review aimed to identify the impact of genetics on the relationship between caffeine consumption and cardiometabolic outcomes. Electronic databases (PubMed and EMBASE) were searched for studies published until July 2021. Selected studies were of both intervention and observational design and included (1) analysis of at least one of the selected cardiometabolic outcome (type 2 diabetes, glucose/insulin levels, cardiovascular disease [CVD], blood pressure [BP] or hypertension, and blood lipid and catecholamine levels), (2) adults aged 18-65 years, and (3) genetic analysis of individuals consuming caffeine. Seventeen studies were included: four randomised controlled trials and an interventional and quasi-experimental study, six population-based prospective cohort studies, three cross-sectional studies, and three case-control studies. CYP1A2 rs762551 and ADORA rs5751876 were associated with glucose response when caffeine was consumed with carbohydrates. CYP1A2 rs762551 moderated the association between coffee intake and hypertension. Moreover, ADORA2A rs5751876 and the ADRA2B I variants moderated the associations between caffeine and BP. Studies that investigated the effects of genetic variations on CVD and caffeine consumption reported equivocal findings (CYP1A2) or warrant replication (COMT, ADORA and TRIB1). Elucidating the extent to which these genes moderate the association between caffeine and cardiometabolic outcomes will enable caffeine consumption advice to be tailored to specific individuals to optimise health.

How Long Is Long Enough? Controlling for Acute Caffeine Intake in Cardiovascular Research

Caffeine substantially affects cardiovascular functioning, yet wide variability exists in caffeine control procedures in cardiovascular reactivity research. This study was conducted in order to identify a minimal abstention duration in habitual coffee consumers whereby cardiovascular reactivity is unconfounded by caffeine; Six hours (caffeine's average half-life) was hypothesized. Thirty-nine subjects (mean age: 20.9; 20 women) completed a repeated measures study involving hand cold pressor (CP) and memory tasks. Caffeinated and decaffeinated coffee were administered. The following cardiovascular indices were acquired during pre-task, task, and post-task epochs prior to coffee intake, 30 min-, and six hours post-intake: Heart rate (HR), high-frequency heart rate variability (HF-HRV), root mean squared successive differences (RMSSD), systolic and diastolic blood pressures (SBP, DBP), mean arterial pressure (MAP), pre-ejection period (PEP), left ventricular ejection time (LVET), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI). Results support the adequacy of a six-hour abstention in controlling for caffeine-elicited cardiovascular changes. The current study offers a suggested guideline for caffeine abstention duration in cardiovascular research in psychophysiology. Consistent practice in caffeine abstention protocols would promote validity and reliability across such studies.

The Effects of Acute Caffeine Supplementation on Repeated-Sprint Ability in Healthy Young Non-Athletes

The ergogenic effects of caffeine supplementation on repeated-sprint ability (RSA) have produced equivocal results. This study aimed to examine the effects of 200 mg of caffeine during repeated-sprint running on heart rate (HR), rating of perceived exertion (RPE), blood lactate (BLa) concentration, and sprint time (ST). Thirty-two individuals (males: n = 17, females: n = 15; age: 22 ± 1 years) participated in the study. The study followed a double-blind, randomized, placebo-controlled, crossover design, in which each participant ingested 200 mg of caffeine or placebo on separate visits 60 minutes prior to repeated-sprinting exercise. The repeated-sprint protocol consisted of three sets of six maximal-effort 30-meter sprints with 20 seconds and 5 minutes of active recovery in between sprints and sets, respectively. During each set, HR, RPE, BLa, and ST were recorded. Caffeine supplementation did not significantly (set 1: p = 0.535; set 2: p = 0.602; set 3: p = 0.189) impact HR during exercise. Similarly, RPE was not statistically (p = 0.052) altered between conditions during any of the sprint sets. The caffeine trials elicited greater BLa values after all three sets compared to the placebo trials (p < 0.001). Moreover, the caffeine trials demonstrated significantly reduced total STs during all sets compared to the placebo trials (p < 0.001). Thus, our findings suggested that 200 mg of caffeine supplementation elicited an increase in RSA in young, healthy non-athletes. These findings are accompanied by a blunted perceived exertion relative to an increase in exercise intensity during repeated-sprint exercise.

Time to Recover From Daily Caffeine Intake

Caffeine elicits widespread effects in the central nervous system and is the most frequently consumed psychostimulant worldwide. First evidence indicates that, during daily intake, the elimination of caffeine may slow down, and the primary metabolite, paraxanthine, may accumulate. The neural impact of such adaptions is virtually unexplored. In this report, we leveraged the data of a laboratory study with N = 20 participants and three within-subject conditions: caffeine (150 mg caffeine × 3/day × 10 days), placebo (150 mg mannitol × 3/day × 10 days), and acute caffeine deprivation (caffeine × 9 days, afterward placebo × 1 day). On day 10, we determined the course of salivary caffeine and paraxanthine using liquid chromatography-mass spectrometry coupled with tandem mass spectrometry. We assessed gray matter (GM) intensity and cerebral blood flow (CBF) after acute caffeine deprivation as compared to changes in the caffeine condition from our previous report. The results indicated that levels of paraxanthine and caffeine remained high and were carried overnight during daily intake, and that the levels of paraxanthine remained elevated after 24 h of caffeine deprivation compared to placebo. After 36 h of caffeine deprivation, the previously reported caffeine-induced GM reduction was partially mitigated, while CBF was elevated compared to placebo. Our findings unveil that conventional daily caffeine intake does not provide sufficient time to clear up psychoactive compounds and restore cerebral responses, even after 36 h of abstinence. They also suggest investigating the consequences of a paraxanthine accumulation during daily caffeine intake.

Methodological review of caffeine assessment strategies with a focus on adolescents

Adolescent caffeine use and its implications for developmental changes in sleep and circadian rhythms is under-researched. A majority of adolescents report consuming caffeine and yet the United States has not established federal guidelines for this age group. This widely used stimulant is primarily studied using self-report methodologies; however, there is no standardized method for collecting self-report caffeine data and past studies' findings have limited generalizability and comparability, making it challenging to examine the effects of caffeine use on adolescents' sleep. This review discusses methods and measures used for assessing caffeine in the field with adolescents: questionnaires, interviews, and diaries. Based on the review, recommendations for future methodologies and approaches are discussed.

Caffeine's Effects on an Upper-Body Resistance Exercise Workout

Salatto, RW, Arevalo, JA, Brown, LE, Wiersma, LD, and Coburn, JW. Caffeine's effects on an upper-body resistance exercise workout. J Strength Cond Res 34(6): 1643-1648, 2020-The purpose of this study was to examine the effects of caffeine on an upper-body resistance exercise workout. Fifteen men (mean ± SD: age, 23.1 ± 1.9 years; body mass, 89.1 ± 13.9 kg; height, 175 ± 6.1 cm) volunteered to come to the laboratory 3 times. During visit 1, 1-repetition maximum (RM) values were determined for the barbell bench press, incline barbell bench press, and dumbbell bench press exercises. For visit 2, subjects consumed either 800-mg caffeine or a placebo. Subjects then completed 3 sets to failure of each exercise using 80% of their 1RM. Visit 3 was the same as visit 2; however, participants consumed the opposite treatment as visit 2. Various perceptual measures were recorded before, during, and after the workouts. The results indicated that participants completed significantly more repetitions per set for the barbell bench press (4.80 ± 2.66) and incline barbell bench press (4.91 ± 2.29) in the caffeine condition compared with the placebo condition (4.42 ± 2.56 and 4.36 ± 2.11, respectively). Higher arousal scores were found in the caffeine condition. For vigor, participants reported higher scores with caffeine before warming up (caffeine = 10.20 ± 4.11, placebo = 6.20 ± 3.23) and mid workout (caffeine = 13.53 ± 2.29, placebo = 11.13 ± 2.79). These results suggest that caffeine has an ergogenic effect on strength workout performance due, at least in part, to positive effects on workout perception. Athletes and recreational lifters may want to consider the ingestion of caffeine before a resistance exercise workout.

Caffeine increases strength and power performance in resistance-trained females during early follicular phase

The effects of 4 mg·kg^-1 caffeine ingestion on strength and power were investigated for the first time, in resistance-trained females during the early follicular phase utilizing a randomized, double-blind, placebo-controlled, crossover design. Fifteen females (29.8 ± 4.0 years, 63.8 ± 5.5 kg [mean ± SD]) ingested caffeine or placebo 60 minutes before completing a test battery separated by 72 hours. One-repetition maximum (1RM), repetitions to failure (RTF) at 60% of 1RM, was assessed in the squat and bench press. Maximal voluntary contraction torque (MVC) and rate of force development (RFD) were measured during isometric knee extensions, while utilizing interpolated twitch technique to measure voluntary muscle activation. Maximal power and jump height were assessed during countermovement jumps (CMJ). Caffeine metabolites were measured in plasma. Adverse effects were registered after each trial. Caffeine significantly improved squat (4.5 ± 1.9%, effect size [ES]: 0.25) and bench press 1RM (3.3 ± 1.4%, ES: 0.20), and squat (15.9 ± 17.9%, ES: 0.31) and bench press RTF (9.8 ± 13.6%, ES: 0.31), compared to placebo. MVC torque (4.6 ± 7.3%, ES: 0.26), CMJ height (7.6 ± 4.0%, ES: 0.50), and power (3.8 ± 2.2%, ES: 0.24) were also significantly increased with caffeine. There were no differences in RFD or muscle activation. Plasma [caffeine] was significantly increased throughout the protocol, and mild side effects of caffeine were experienced by only 3 participants. This study demonstrated that 4 mg·kg^-1 caffeine ingestion enhanced maximal strength, power, and muscular endurance in resistance-trained and caffeine-habituated females during the early follicular phase, with few adverse effects. Female strength and power athletes may consider using this dose pre-competition and -training as an effective ergogenic aid.

The enhancing effect of 200 mg caffeine on mnemonic discrimination is at best small

Mnemonic discrimination is the ability to discriminate among similar memories, which requires separable representations of similar information. The neurocomputational process that assumedly decorrelates representations during encoding and consolidation is referred to as pattern separation. Deficits in pattern separation contribute to age-related declines in mnemonic functioning, which has motivated the development of targeted interventions. We followed-up a recent report that one 200 mg-dose of caffeine administered post-study enhances mnemonic discrimination [Borota, D., Murray, E., Keceli, G., Chang, A., Watabe, J. M., Ly, M., Toscano, J. P., & Yassa, M. A. (2014). Post-study caffeine administration enhances memory consolidation in humans. Nature Neuroscience, 17(2), 201-203. https://doi.org/10.1038/nn.3623]. To test whether the reported enhancements are an artifact of performance-impairing withdrawal symptoms in the control group, we did not restrict preexperimental caffeine intake and statistically adjusted treatment effects for habitual caffeine consumption. We detected no effects of caffeine and nonsuperiority testing ruled out medium and large enhancements in both average (1200 mg per week) and low-consumers (50 mg per week). Our results raise doubts about a caffeine-mediated enhancement of mnemonic discrimination on two counts: If the effect exists, it (1) is substantially smaller than originally reported and (2) may reflect an offset of performance-impairing withdrawal symptoms rather than genuinely enhanced consolidation. We recommend that future studies employ an alternating exposure-abstinence protocol, use an active control group, and verify posttreatment caffeine abstinence via saliva or blood samples.

Investigating associations between caffeinated beverage consumption and later alcohol consumption among early adolescents

Previous research has demonstrated that caffeinated beverage consumption predicts alcohol consumption among early adolescents. This study aimed to investigate this association in two ways: (1) by examining if this association remained significant once other established risk factors for alcohol were adjusted for statistically; and (2) by considering three possible moderators of this association: gender, sensation-seeking, and parental monitoring. Data from the Camden Youth Development Study, a longitudinal, community-based study of middle-school students, were used. Youth were initially assessed in 6th and 7th grade and followed-up 16 months later. Self-reports of frequency of energy drink, coffee, and alcohol consumption, as well as sensation-seeking, perceived peer and best friend alcohol use, alcohol expectancies, and parental monitoring, were used. Results indicated that both energy drink and coffee consumption predicted later alcohol consumption, even after adjusting for other risk factors for alcohol consumption. Parental monitoring was a significant moderator of this link, such that youth who consumed energy drinks and reported low parental monitoring were particularly at risk for later alcohol consumption. These findings indicate that the link between earlier caffeine consumption and later alcohol consumption is not simply due to the co-occurrence of caffeine consumption with other risk factors for alcohol use. In addition, risk associated with early energy drink consumption appears to be particularly pronounced for youth in families characterized by low parental monitoring.

Controlling for caffeine in cardiovascular research: A critical review

Caffeine, the most widely consumed drug in the world, exerts numerous effects on cardiovascular activity. Thus, it is important and advisable to control for caffeine consumption in studies examining caffeine and/or cardiovascular activity and reactivity. This paper 1) reviews the literature concerning caffeine's effects on cardiovascular parameters; 2) summarizes the widely varying protocols used to control for the drug in extant cardiovascular literature, and 3) provide guidelines for caffeine control procedures to minimize potentially confounding acute and withdrawal effects of the drug. An abstention period equal to the average half-life of the drug is recommended for creation of methodological controls for caffeine. Additional methodological recommendations are described concerning factors that moderate the half-life of caffeine. When feasible, researchers should consider and aim to control for caffeine's acute and extended psychophysiological effects. This understudied issue has fundamental implications for caffeine-related investigations and research in psychophysiology and behavioral medicine.

Higher habitual dietary caffeine consumption is related to lower experimental pain sensitivity in a community-based sample

RATIONALE

Caffeine is the most widely consumed psychoactive substance in the world. Caffeine administered acutely in a laboratory environment or as a medication adjuvant has known properties that help alleviate pain. However, much less is known about the potential impact of habitual dietary caffeine consumption on the experience of pain.

OBJECTIVES

The primary objective of this observational study was to determine whether caffeine consumed habitually as part of a daily diet was associated with experimental pain sensitivity using noxious stimuli in a non-clinical sample of 62 community-dwelling adults between 19 and 77 years old.

METHODS

Study participants monitored their daily dietary caffeine consumption (e.g., coffee, tea, soda, energy drinks, and chocolate) across a period of seven consecutive days using a caffeine consumption diary. On the seventh day of caffeine consumption monitoring, participants presented to the laboratory to complete experimental pain sensitivity testing. Noxious thermal and mechanical stimuli were used to obtain threshold and tolerance for painful heat and pressure, respectively.

RESULTS

Data analysis revealed that greater self-reported daily caffeine consumption was significantly associated with higher heat pain threshold (β = .296, p = .038), higher heat pain tolerance (β = .242, p = .046), and higher pressure pain threshold (β = .277, p = .049) in multiple regression models adjusted for covariates.

CONCLUSIONS

Results of this study completed with community-dwelling adults revealed that individuals who habitually consume greater amounts of caffeine as part of their daily diets demonstrate diminished sensitivity to painful stimuli in a laboratory setting.

Caffeine increases the velocity of rapid eye movements in unfatigued humans

BACKGROUND

Caffeine is a widely used dietary stimulant that can reverse the effects of fatigue on cognitive, motor and oculomotor function. However, few studies have examined the effect of caffeine on the oculomotor system when homeostasis has not been disrupted by physical fatigue. This study examined the influence of a moderate dose of caffeine on oculomotor control and visual perception in participants who were not fatigued.

METHODS

Within a placebo-controlled crossover design, 13 healthy adults ingested caffeine (5 mg·kg^-1 body mass) and were tested over 3 h. Eye movements, including saccades, smooth pursuit and optokinetic nystagmus, were measured using infrared oculography.

RESULTS

Caffeine was associated with higher peak saccade velocities (472 ± 60° s^-1) compared to placebo (455 ± 62° s^-1). Quick phases of optokinetic nystagmus were also significantly faster with caffeine, whereas pursuit eye movements were unchanged. Non-oculomotor perceptual tasks (global motion and global orientation processing) were unaffected by caffeine.

CONCLUSIONS

These results show that oculomotor control is modulated by a moderate dose of caffeine in unfatigued humans. These effects are detectable in the kinematics of rapid eye movements, whereas pursuit eye movements and visual perception are unaffected. Oculomotor functions may be sensitive to changes in central catecholamines mediated via caffeine's action as an adenosine antagonist, even when participants are not fatigued.

Caffeine consumption patterns and determinants among adolescents in Serbia

BACKGROUND

The number of adolescents who use caffeine is constantly increasing. As juvenile age is vulnerable, it is reasonable to expect that they will differently perceive reason and react to caffeine use than adults, and be more prone to unwanted physiological and psychological consequences of its consumption.

AIM

Analysis of the scope and pattern of caffeine consumption among adolescents in Serbia.

STUDY DESIGN

The cross-sectional survey was implemented in the study population of 191 Serbian adolescents during 2010.

RESULTS

The median daily intake of caffeine was 95.6 mg. The major source of caffeine was brewed coffee, and the most common reasons for caffeine intake were leisure, peer influence, or habit. Only 57.6% of the subjects were aware that caffeine is present in consumed beverages. Sex affected the pattern, but not the overall level, of caffeine consumption. No association between caffeine consumption and smoking status, frequency of caffeine use in the family, or negative personal experience with caffeine effects was observed.

CONCLUSION

Our investigation provides first and rather detailed insight into caffeine-containing beverage consumption scope and pattern among Serbian adolescents. For accurate estimation and analysis of caffeine intake in this population, randomized studies with prospective longitudinal design, caffeine content measurement, and more subjects involved are warranted.

Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake

BACKGROUND

Coffee consumption is a known inducer of cytochrome P450 1A2 (CYP1A2) enzyme activity. We recently observed that a group of type-2 diabetes patients consumed more caffeine (coffee) on a daily basis than non-type-2 diabetes controls. Here, we investigated whether type-2 diabetes cases may metabolize caffeine faster than non-type-2 diabetes controls.

METHODS

To estimate CYP1A2 enzyme activity, an established marker of caffeine metabolism, we quantified the paraxanthine/caffeine concentration ratio in saliva in 57 type-2 diabetes and 146 non-type-2 diabetes participants in a case-control field study. All participants completed validated questionnaires regarding demographic status, health and habitual caffeine intake, and were genotyped for the functional -163C > A polymorphism of the CYP1A2 gene.

RESULTS

In the diabetes group, we found a larger proportion of participants with the highly inducible CYP1A2 genotype. Furthermore, the paraxanthine/caffeine ratio, time-corrected to mitigate the impact of different saliva sampling times with respect to the last caffeine intake, was higher than in the control group. Participants who reported habitually consuming more caffeine than the population average showed higher CYP1A2 activity than participants with lower than average caffeine consumption. Multiple regression analyses revealed that higher caffeine intake was potentially an important mediator of higher CYP1A2 activity.

CONCLUSIONS

Estimated CYP1A2 enzyme activity, and thus speed of caffeine metabolism, was higher in our type-2 diabetes group; this was possibly due to higher intake of caffeine, a known inducer of CYP1A2 enzyme activity. Given the fairly small sample sizes, the results need to be considered as preliminary and require validation in larger populations.

Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine

OBJECTIVE

Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake.

METHODS

Data were analyzed from a large phase 3 placebo-controlled clinical study of creatine as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 movement disorders centers across the United States and Canada. A total of 1741 subjects with PD participated in the primary clinical study, and caffeine intake data were available for 1549 of these subjects. The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified Parkinson Disease Rating Scale score and the interaction of this association with creatine intake were assessed.

RESULTS

Caffeine intake was not associated with the rate of progression of PD in the main analysis, but higher caffeine intake was associated with significantly faster progression among subjects taking creatine.

CONCLUSIONS

This is the largest and longest study conducted to date that addresses the association of caffeine with the rate of progression of PD. These data indicate a potentially deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.

Acute personalized habitual caffeine doses improve attention and have selective effects when considering the fractionation of executive functions

Caffeine is widely used, often consumed with food, and improves simple and complex/executive attention under fasting conditions. We investigated whether these cognitive effects are observed when personalized habitual doses of caffeine are ingested by caffeine consumers, whether they are influenced by nutriments and if various executive domains are susceptible to improvement. This was a double-blind, placebo-controlled study including 60 young, healthy, rested males randomly assigned to one of four treatments: placebo fasting, caffeine fasting, placebo meal and caffeine meal. Caffeine doses were individualized for each participant based on their self-reported caffeine consumption at the time of testing (morning). The test battery included measures of simple and sustained attention, executive domains (inhibiting, updating, shifting, dual tasking, planning and accessing long-term memory), control measures of subjective alterations, glucose and insulin levels, skin conductance, heart rate and pupil dilation. Regardless of meal intake, acute habitual doses of caffeine decreased fatigue, and improved simple and sustained attention and executive updating. This executive effect was not secondary to the habitual weekly dose consumed, changes in simple and sustained attention, mood, meal ingestion and increases in cognitive effort. We conclude that the morning caffeine "fix" has positive attentional effects and selectively improved executive updating whether or not caffeine is consumed with food.

Sleep, Aggression, and Psychosocial Adjustment in Male Prisoners

In this study, we investigate sleep quantity and quality and their association with anger-related reactions, symptoms of ADHD, depressive symptoms, physical health complaints, and life satisfaction in male prison inmates. Furthermore, we examine whether good sleep hygiene in the prison context (physical exercise during the day, switching the television off at night, limiting caffeine and cigarette consumption) is related to sleep quantity and quality. Forty-nine prison inmates (mean age = 39.37; SD = 13.95) completed questionnaires assessing sleep quality and quantity, sleep hygiene, and psychosocial and physical functioning. Short sleep duration (6 h or less) and poor sleep quality were related to higher levels of aggressiveness in aggression-provoking social situations and more physical health complaints. In addition, poor sleep quality was related to higher levels of rumination and more symptoms of ADHD. Daily caffeine consumption, a sleep hygiene variable, was related to shorter sleep duration. The results suggest that, among a sample of male prison inmates, adequate sleep duration and good sleep quality were associated with better psychosocial adjustment.

Validation of different instruments for caffeine measurement among premenopausal women in the BioCycle study

Effects of caffeine on women's health are inconclusive, in part because of inadequate exposure assessment. In this study we determined 1) validity of a food frequency questionnaire compared with multiple 24-hour dietary recalls (24HDRs) for measuring monthly caffeine and caffeinated beverage intakes; and 2) validity of the 24HDR compared with the prior day's diary record for measuring daily caffeinated coffee intake. BioCycle Study (2005-2007) participants, women (n = 259) aged 18-44 years from western New York State, were followed for 2 menstrual cycles. Participants completed a food frequency questionnaire at the end of each cycle, four 24HDRs per cycle, and daily diaries. Caffeine intakes reported for the food frequency questionnaires were greater than those reported for the 24HDRs (mean = 114.1 vs. 92.6mg/day, P = 0.01) but showed high correlation (r = 0.73, P < 0.001) and moderate agreement (К = 0.51, 95% confidence interval: 0.43, 0.57). Women reported less caffeinated coffee intake in their 24HDRs compared with their corresponding diary days (mean = 0.51 vs. 0.80 cups/day, P < 0.001) (1 cup = 237 mL). Although caffeine and coffee exposures were highly correlated, absolute intakes differed significantly between measurement tools. These results highlight the importance of considering potential misclassification of caffeine exposure.

The Effects of Dietary Caffeine Use and Abstention on Blood Oxygen Level-Dependent Activation and Cerebral Blood Flow

BACKGROUND

Caffeine is a known vasoconstrictor that reduces resting cerebral blood flow (CBF) throughout the brain. This effect may be problematic in functional magnetic resonance imaging (fMRI) research, as the blood oxygen level-dependent (BOLD) signal is a complex interaction of CBF and other factors that are dependent on changes in neural activity. It is unknown whether changes in the BOLD signal during an fMRI experiment could be affected by subjects' recent use or abstinence from dietary caffeine.

METHODS

Here, we report two similar studies (n=45 and 17) that measure the effects of caffeine on BOLD activation, BOLD time course parameters, and CBF. Using a factorial design, low, moderate, and high caffeine consumers received either caffeine (250 mg) or placebo during normal caffeine use (satiated state) or after 30 hours of abstention (abstinent state). The fMRI of a reaction time task and resting-state CBF were collected.

RESULTS

In general, acute caffeine administration reduced the time to peak and full width at half maximum of the BOLD time course, and CBF across both studies. Caffeine also produced a small reduction in BOLD activation. The majority of these reductions across measures were moderated by neither the level of caffeine use, nor the abstinent or satiated state.

CONCLUSIONS

These results suggest that dietary caffeine use does not produce a significant effect on task-related BOLD activation.

Individual differences affecting caffeine intake. Analysis of consumption behaviours for different times of day and caffeine sources

The main purpose of the present study was to investigate the individual variables contributing to determine the high variability in the consumption behaviours of caffeine, a psychoactive substance which is still poorly investigated in comparison with other drugs. The effects of a large set of specific personality traits (i.e., Impulsivity, Sensation Seeking, Anxiety, Reward Sensitivity and Circadian Preference) were compared along with some relevant socio-demographic variables (i.e., gender and age) and cigarette smoking behaviour. Analyses revealed that daily caffeine intake was significantly higher for males, older people, participants smoking more cigarettes and showing higher scores on Impulsivity, Sensation Seeking and a facet of Reward Sensitivity. However, more detailed analyses showed that different patterns of individual variables predicted caffeine consumption when the times of day and the caffeine sources were considered. The present results suggest that such detailed analyses are required to detect the critical predictive variables that could be obscured when only total caffeine intake during the entire day is considered.

alcohol, smoking, and caffeine in relation to fecundability, with effect modification by NAT2

PURPOSE

Common polymorphisms in the N-acetyltransferase-2 (NAT2) metabolic enzyme determine slow or rapid acetylator phenotypes. We investigated the effects of alcohol, smoking, and caffeine on fecundability, and determined whether the effects were modified by NAT2.

METHODS

Three NAT2 polymorphisms were genotyped in 319 women office workers participating in a prospective pregnancy study (1990-1994). Women were ages 20-41 and at risk for pregnancy. Discrete-time survival analysis was used to determine the effects of alcohol, smoking, and caffeine on fecundability and evaluate effect modification by NAT2.

RESULTS

We followed 319 women (161 slow acetylators, 158 rapid) for an average of 8 menstrual cycles, resulting in 124 pregnancies. There was no effect of caffeine on fecundability. Drinking ≥1 alcoholic drink per day and current smoking were significantly associated with reduced fecundability, but only among slow acetylators (adjusted fecundability odds ratio [FOR] for smoking = 0.34; 95% confidence interval, 0.22-0.90; adjusted FOR for ≥1 drink per day = 0.20; 0.05-0.92). There was no effect among rapid acetylators.

CONCLUSIONS

NAT2 status significantly modified the effects of alcohol and smoking on fecundability, emphasizing the importance of incorporating genetic and metabolic information in studies of reproductive health. Replication of this study is warranted.

A comparison of the effects of caffeine following abstinence and normal caffeine use

RATIONALE

Caffeine typically produces positive effects on mood and performance. However, tolerance may develop following habitual use, and abrupt cessation can result in withdrawal symptoms, such as fatigue. This study investigated whether caffeine has a greater stimulant effect in a withdrawn state compared to a normal caffeinated state, among moderate daily caffeine consumers.

MATERIALS AND METHODS

Using a within-subjects design, 17 caffeine consumers (mean +/- sd = 375 +/- 101 mg/day) ingested placebo or caffeine (250 mg) following 30-h of caffeine abstention or normal dietary caffeine use on four separate days. Self-reported mood and performance on choice reaction time, selective attention, and memory tasks were measured.

RESULTS

Caffeine had a greater effect on mood and choice reaction time in the abstained state than in the normal caffeinated state, but caffeine improved selective attention and memory in both states.

CONCLUSIONS

Although improvements in mood and reaction time may best explained as relief from withdrawal symptoms, other performance measures showed no evidence of withdrawal and were equally sensitive to an acute dose of caffeine in the normal caffeinated state.

The effect of daily caffeine use on cerebral blood flow: How much caffeine can we tolerate?

Caffeine is a commonly used neurostimulant that also produces cerebral vasoconstriction by antagonizing adenosine receptors. Chronic caffeine use results in an adaptation of the vascular adenosine receptor system presumably to compensate for the vasoconstrictive effects of caffeine. We investigated the effects of caffeine on cerebral blood flow (CBF) in increasing levels of chronic caffeine use. Low (mean = 45 mg/day), moderate (mean = 405 mg/day), and high (mean = 950 mg/day) caffeine users underwent quantitative perfusion magnetic resonance imaging on four separate occasions: twice in a caffeine abstinent state (abstained state) and twice in a caffeinated state following their normal caffeine use (native state). In each state, there were two drug conditions: participants received either caffeine (250 mg) or placebo. Gray matter CBF was tested with repeated-measures analysis of variance using caffeine use as a between-subjects factor, and correlational analyses were conducted between CBF and caffeine use. Caffeine reduced CBF by an average of 27% across both caffeine states. In the abstained placebo condition, moderate and high users had similarly greater CBF than low users; but in the native placebo condition, the high users had a trend towards less CBF than the low and moderate users. Our results suggest a limited ability of the cerebrovascular adenosine system to compensate for high amounts of daily caffeine use.